Discovery May Boost Effectiveness Of Chemotherapy

December 21, 1998

Researchers at the University of Maryland Greenebaum Cancer Center have made a discovery that may explain why some cases of breast cancer and other forms of cancer are resistant to chemotherapy. Their findings, published in the December 22, 1998, issue of Proceedings of the National Academy of Sciences, may lead to better ways to target chemotherapy to individual patients and may open the door to new strategies to reverse resistance to cancer-fighting drugs.

"We have found a cancer resistance protein that rapidly pumps out chemotherapy from a certain line of breast cancer cells," says L. Austin Doyle, M.D., associate professor of medicine at the University of Maryland School of Medicine who is the lead author of the article.

The researchers call the newly-discovered pump Breast Cancer Resistance Protein (BCRP). They found that this protein pumped three common anti-cancer drugs out of cells rapidly, before the drugs could get to the nucleus of the cancer cells and destroy them.

"This is only the fourth molecular drug resistance pump of anti-cancer drugs to be identified, and it is half the size of the other pumps," says Douglas D. Ross, M.D., Ph.D, professor of medicine at the University of Maryland School of Medicine. "We had been looking for years for a way to explain resistance among this group of resistant cancer cells, so this is an important step," adds Dr. Ross, who is a co-author of the article.

The researchers, along with Lynne Abrusso, M.D., Ph.D, assistant professor of pathology at the University of Maryland School of Medicine, studied resistant and non-resistant cancer cells to find genes that were different among the two groups. They used molecular biology techniques to isolate the unique BCRP gene from drug-resistant cancer cells. Then, they tested their theory by changing non-resistant cells into resistant ones by inserting the BCRP gene into them.

"Drug resistance is a big problem for many patients with cancer," says Dr. Doyle. "We are trying to determine which cancers have this type of resistance. In the future, we may be able to help our patients by adding compounds to their chemotherapy that will block the protein products of genes that cause resistance."

One of the drugs these resistant cancer cells are able to pump away is mitoxantrone, a common first-line chemotherapy which is less toxic than many other anti-cancer drugs. It is often prescribed for breast cancer, leukemia, colon cancer and myeloma. "With these findings, we may be able to make this good drug even better," says Dr. Ross.

Mitoxantrone-resistant cell lines from breast, stomach and colon cancers as well as multiple myeloma all were found to have increased levels of the new cancer resistance protein.

The researchers are working on ways to overcome this newly-discovered form of resistance and improve the effectiveness of chemotherapy. Recently, they have tested a new compound that turns off the newly-discovered resistance protein and restores the ability of mitoxantrone and other chemotherapy drugs to kill cancer cells successfully.

Researchers at the University of Maryland Greenebaum Cancer Center are involved in a wide variety of basic and clinical research. The center provides a complete range of specialized services for all aspects of cancer care, and patients have access to promising new therapies before they are widely available.
-end-
Reporters note: To receive a copy of the paper, please contact the National Academy of Sciences News Office at 202-334-2138.



University of Maryland Medical Center

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.